Also known as primary biliary cirrhosis (PBC), biliary cirrhosis is an autoimmune disease that damages the small bile ducts in the liver. This long-term disease leads to the accumulation of bile in the liver, thereby destroying the liver and eventually leading to cirrhosis. The commonly noted symptoms of biliary cirrhosis are yellowing of the skin, dryness of the mouth and eyes, itchy skin, abdominal pain, and excessive fatigue.
Future Perspective of Biliary Cirrhosis Market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3352
The global biliary cirrhosis market is being driven by the increasing number of women suffering from this disease due to liver damage or other liver-related diseases. Biliary cirrhosis is more common among women. Technological developments in diagnostic testing equipment are also propelling this market. Furthermore, supportive reimbursement policies and medical coverage are expected to boost this market in the coming years.
Several players across the globe are investing in research and development activities for devising enhanced techniques to diagnose this disease at an early stage. Timely diagnosis can help save the liver and reduce the pain. Liver transplantation and other complications can also be avoided with early diagnoses.
The global biliary cirrhosis market is segmented on the basis of treatments into corticosteroids, ursodeoxycholic acid (UDCA), treatment for itchiness, and liver transplant. On the basis of diagnostic tests, this market is divided into complete blood count (CBC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase bilirubin, cholesterol level test, and other imaging tests such as magnetic resonance imaging, computerized tomography, and ultrasound. Geographically, this market is segmented into Asia Pacific, North America, Europe, and Rest of the World. The research report includes a SWOT analysis that highlights the strengths, weaknesses, opportunities, and threats impacting the segments of the global biliary cirrhosis market
GlaxoSmithKline plc, Pfizer, Inc., Lumena Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Johnson & Johnson, and Teva Pharmaceuticals USA, Inc. are some of the important players operating in the global biliary cirrhosis market. The report has evaluated the competitive landscape in complete detail to provide its readers a clear picture of the looming threat from new entrants and the degree of competitive rivalry present in the overall market. The report also details the research and development activities, financial overview, investment outlook, business and marketing strategies, and strategic mergers and acquisition activities of these top players in the global biliary cirrhosis market.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453